UBS AM’s Astria Therapeutics ATXS Stock Holding History

UBS AM’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,935	Closed	-$25.3K	–	3811
2025 Q4	$25.3K	Buy	+1,935	New	+$23.1K	﹤0.01%	2705
2025 Q2	–	Sell	-63,452	Closed	-$339K	–	2626
2025 Q1	$339K	Hold	63,452	–	–	﹤0.01%	2546
2024 Q4	$567K	Buy	63,452 +7,756	+14%	+$82.4K	﹤0.01%	2538
2024 Q3	$613K	Buy	+55,696	New	+$619K	﹤0.01%	2586

UBS AM's ATXS Position: Q1 2026 in Review

UBS AM sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,935 shares — an estimated $25.3K sold.

UBS AM first reported a position in ATXS in Q3 2024 and held it in 4 quarters. The position peaked at $613K in Q3 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

UBS AM reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
UBS AM sold 1,935 Astria Therapeutics shares in Q1 2026, an estimated $25.3K.
UBS AM first reported a position in Astria Therapeutics in Q3 2024 and held it in 4 quarters.
UBS AM's Astria Therapeutics position peaked at $613K in Q3 2024.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.